Clinical Trial: Tocilizumab Combined With First-Line Chemo-Immunotherapy in Metastatic Non-Small Cell Lung Cancer

U.S., Oct. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07889232) titled 'Tocilizumab Combined With First-Line Chemo-Immunotherapy in Metastatic Non-Small Cell Lung Cancer' on Sept. 18.

Brief Summary: This is a Phase 1b/2, multi-site, single-arm, open-label, non-randomized study looking at whether adding tocilizumab to standard treatment for metastatic Non-Small Cell Lung Cancer (NSCLC) is safe, possible, and effective. The study includes people with metastatic NSCLC, that is lung cancer that has spread, who have experienced significant loss of weight or muscle mass.

Study Start Date: Nov. 01

Study Type: INTERVENTIONAL

Condition: Metastatic Non-Small Cell Lung Cancer Cancer-Associated Weight Loss Elev...